Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492987 | 1.00 | MTNR1A (0.38) | MTNR1AMTNR1BDPP8DPP9AAK1 | |
| SCHEMBL21812802 | 0.86 | MTNR1A (0.36) | MTNR1AMTNR1BDPP8DPP9MIF | |
| SCHEMBL30267728 | 0.83 | MME (0.37) | POLBMAPT | |
| SCHEMBL3700526 | 0.83 | MME (0.37) | POLBMAPT | |
| SCHEMBL8903076 | 0.82 | PKM (0.32) | MTNR1AMTNR1BPKMLMNAMAPT | |
| SCHEMBL8902403 | 0.82 | LMNA (0.34) | MTNR1AMTNR1BPKMLMNA | |
| SCHEMBL8903941 | 0.79 | PKM (0.34) | PKMLMNA | |
| SCHEMBL29193914 | 0.74 | POLB (0.36) | KDM4EPOLB | |
| SCHEMBL8903861 | 0.73 | CYP4F2 (0.46) | PKMLMNAMAPT | |
| SCHEMBL260291 | 0.70 | BRD4 (0.43) | LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-04-29 | — | — | US | disclosed |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-03-11 | — | — | US | disclosed |
| CN-113166084-B | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-113166085-B | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2022-04-14 | — | — | US | disclosed |
| CN-113166085-A | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166084-A | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2020-05-21 | — | — | US | disclosed |
| EP-3628666-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628672-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628672-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| CN-110914238-A | Compounds as antibiotics | 安塔比奥公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3601224-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | Antabio SAS (FR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172423-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ARG1, ELANE, INSR | MTNR1A 485/4885MTNR1B 607/4885DPP8 1536/4885 |
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | MTNR1A 424/4885MTNR1B 549/4885DPP8 1514/4885 |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | MRPL21, CFTR, H1-0 | MTNR1A 1710/4885MTNR1B 1430/4885DPP8 727/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | MTNR1A 385/4885MTNR1B 295/4885DPP8 2754/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | MTNR1A 1710/4885MTNR1B 1430/4885DPP8 727/4885 |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | MTNR1A 424/4885MTNR1B 549/4885DPP8 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.